Items Tagged ‘News’

June 13, 2019

FDA Approves Keytruda for First-line Treatment of Head and Neck Squamous Cell Carcinoma

By

FDA approves Keytruda for the first-line treatment of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC). Keytruda was approved for use in combination with platinum and fluorouracil (FU) for all patients and as a single agent for patients whose tumors express PD‑L1 (Combined Positive Score [CPS] ≥1) as determined by […]

View full entry

Tags: Head and Neck Cancer, News


June 11, 2019

FDA Approves Chemoimmunotherapy Regimen for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

By

The U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy Treanda (bendamustine) and Rituxan (rituximab) product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. About Polivy Polivy is a […]

View full entry

Tags: Hodgkin's Lymphoma, News


June 10, 2019

Three-drug Combination Helps Curb Growth of Deadly Skin Cancer

By

A UCLA-led research team has pinpointed a three-drug combination that could prove to be an effective new therapy for people with a specific type of advanced melanoma. The approach shows promise for extending the lives of people with a type of melanoma that contains a potent gene mutation, BRAF V600E. In clinical trials, it appeared […]

View full entry

Tags: News, Skin Cancer


June 4, 2019

Immunotherapy comparable to chemo for some advanced stomach cancers

By

An immunotherapy drug could prove just as effective as chemotherapy in prolonging the lives of patients with advanced cancers of the stomach or food pipe. For some, the immune-boosting treatment offered improved survival compared to standard treatment. The immunotherapy, called pembrolizumab (Keytruda), was most effective for patients whose cancers carry high levels of a molecule […]

View full entry

Tags: Gastric Cancer, News


June 3, 2019

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer

By

After 3 years, 80% of men with metastatic hormone-sensitive prostate cancer who received enzalutamide along with testosterone suppression were alive compared to 72% of men who received standard care. Chicago – Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented during […]

View full entry

Tags: News, Prostate Cancer


May 30, 2019

FDA approves lenalidomide for follicular and marginal zone lymphoma

By

On May 28, 2019, the Food and Drug Administration approved lenalidomide (REVLIMID®, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). The MAGNIFY clinical trial evaluated 232 patients with relapsed or refractory FL, MZL, or mantle cell lymphoma treated with lenalidomide and rituximab. […]

View full entry

Tags: News, Non-Hodgkin's Lymphoma


May 29, 2019

Piqray® approved for the treatment of postmenopausal women with breast cancer

By

The US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer.[1] PIK3CA is the most commonly mutated gene in HR+/HER2- breast cancer; approximately 40% of patients […]

View full entry

Tags: Breast Cancer, News


May 20, 2019

Calquence Improves Survival in Relapsed Chronic Lymphocytic Leukemia

By

An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable results. (1) About chronic lymphocytic leukemia CLL is the most common type of leukemia in adults. (2) with an average age […]

View full entry

Tags: Chronic Lymphoblastic Leukemia, Genetics, germline mutations, Hereditary Caner Test, hereditary risk, Leukemia, myRisk, News, Prostate Cancer


May 7, 2019

Zytig Treatment Prolongs Survival in Advanced Prostate Cancer

By

Zytig (Abiraterone acetate) plus prednisone and androgen deprivation therapy (ADT) significantly extends overall survival compared with placebo plus ADT in men with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (CSPC) About Zytig Zytiga is an oral targeted agent that blocks the production of androgens (male hormones such as testosterone) not only by the testes, but […]

View full entry

Tags: News, Prostate Cancer


May 7, 2019

FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation

By

On May 2, 2019, the Food and Drug Administration approved ivosidenib (TIBSOVO, Agios Pharmaceuticals, Inc.) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy. Approval was […]

View full entry

Tags: Leukemia, News


May 6, 2019

Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer

By

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness – increasing patient convenience. Dr. Jackisch M.D. and colleagues reported the results of an open-label, multi-center, international clinical trial to […]

View full entry

Tags: Breast Cancer, News


May 3, 2019

Ice Chips May Be The Easiset Way to Reduce Mucositis From Cancer Treatment

By

A new study in the April 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network reports that oral cryotherapy reduce mucositis related side effects. Ice chips or “cryotherapy” has long been used to reduce the intensity of mouth sores called mucositis that occur following treatment with stem cell transplant and certain chemotherapy drugs. This current study enrolled 50 […]

View full entry

Tags: News


May 1, 2019

ASCO Guideline: Oxaliplatin Adjuvant Therapy for Stage III Colon Cancer May Be Reduced in Select Patients

By

The American Society of Clinical Oncology (ASCO) has released a new guideline that states that patients with clinically low-risk stage III colon cancer should have the option of receiving 3 months of adjuvant oxaliplatin-based chemotherapy. For patients at a high risk of recurrence (T4 and/or N2), adjuvant chemotherapy should be offered for a duration of […]

View full entry

Tags: Colon Cancer, News


April 30, 2019

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer

By

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer (ESBC).(1) In the United States “dose dense” chemotherapy is considered standard of care for the treatment […]

View full entry

Tags: Breast Cancer, News


April 16, 2019

FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma

By

granted accelerated approval to Balversa (erdafitinib) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for erdafitinib. Today, […]

View full entry

Tags: Bladder Cancer, News